Apogee Therapeutics, Inc. (APGE): Results of Operations and Financial Condition
Apogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worl
How this was made
The 30-second read
Why it matters
The 8-K combines (1) a definitive AbbVie acquisition agreement with a specified per-share cash price and expected Q3 2026 close, and (2) Q2 financial updates plus positive APEX Phase 2 Part B induction dose-optimization results that support planned Phase 3 advancement.
Market read
For APGE, the dominant tradable catalyst is the announced cash acquisition terms plus supportive clinical efficacy data, which can drive deal-spread and event-volatility trading.
What to watch
The filing does not provide deal financing terms, detailed regulatory pathway, or any new safety signals; traders may need to monitor subsequent filings for closing-condition changes and any Phase 3 protocol adjustments.
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
Positive Phase 2 dose-optimization results and a substantially larger cash and securities position were accompanied by higher research and development, general and administrative, and merger-related costs, resulting in a wider net loss. The pending AbbVie acquisition is expected to close in the third quarter of 2026, subject to closing conditions.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended June 30GAAP | $67.3 million | – | – |
| General and administrative expenses, three months ended June 30GAAP | $24.3 million | – | – |
| Merger transaction costs, three months ended June 30GAAP | $ 4,361 (In thousands) | – | – |
| Total operating expenses, three months ended June 30GAAP | $ 96,004 (In thousands) | – | – |
| Loss from operations, three months ended June 30GAAP | $ (96,004 ) (In thousands) | – | – |
| Interest income, net, three months ended June 30GAAP | $ 11,808 (In thousands) | – | – |
| Interest expense, three months ended June 30GAAP | $ (1,580) (In thousands) | – | – |
| Total other income, net, three months ended June 30GAAP | $ 10,228 (In thousands) | – | – |
| Net loss before taxes, three months ended June 30GAAP | $ (85,776 ) (In thousands) | – | – |
| Provision for income taxes, three months ended June 30GAAP | $ (78 ) (In thousands) | – | – |
| Net loss after taxes, three months ended June 30GAAP | $85.9 million | – | – |
| Research and development expenses, six months ended June 30GAAP | $ 128,120 (In thousands) | – | – |
| General and administrative expenses, six months ended June 30GAAP | $ 46,295 (In thousands) | – | – |
| Merger transaction costs, six months ended June 30GAAP | $ 4,361 (In thousands) | – | – |
| Total operating expenses, six months ended June 30GAAP | $ 178,776 (In thousands) | – | – |
| Loss from operations, six months ended June 30GAAP | $ (178,776 ) (In thousands) | – | – |
| Interest income, net, six months ended June 30GAAP | $ 20,548 (In thousands) | – | – |
| Interest expense, six months ended June 30GAAP | $ (1,580) (In thousands) | – | – |
| Total other income, net, six months ended June 30GAAP | $ 18,968 (In thousands) | – | – |
| Net loss before taxes, six months ended June 30GAAP | $ (159,808 ) (In thousands) | – | – |
| Provision for income taxes, six months ended June 30GAAP | $ (157 ) (In thousands) | – | – |
| Net loss after taxes, six months ended June 30GAAP | $ (159,965 ) (In thousands) | – | – |
| Cash, cash equivalents, marketable securities and long-term marketable securitiesGAAP | $1.3 billion | – | – |
2H 2026, third quarter of 2026, and 1H 2027 outlook
- NoteThe proposed acquisition is expected to close in the third quarter of 2026, subject to customary closing conditions, including shareholder approval and receipt of required regulatory approvals.
- NoteThe ELEVATE Phase 2a trial will initiate in 2H 2026 and is expected to enroll approximately 30 to 50 patients.
- NoteThe ASPIRE Phase 2b trial will initiate in 1H 2027 and is expected to enroll approximately 500 patients.
- NoteInterim data from the Phase 1b head-to-head study of APG279 versus DUPIXENT® are expected in 2H 2026.
- NoteAdditional plans for APG273 are to be announced in 2H 2026.
What drove it
- APEX Phase 2 Part B met all primary and secondary endpoints with high statistical significance.
- 65.9% of patients treated with mid-dose zumilokibart achieved EASI-75, with 41.9% placebo adjusted.
- The company selected the mid-dose regimen for planned Phase 3 initiation this year.
- R&D expense increased primarily from continued development of the zumilokibart program and higher personnel and equity-based compensation expenses associated with research and development team growth.
- G&A expense increased primarily from personnel-related expenses and equity-based compensation driven by increased headcount and an increase in the fair value of equity awards granted.
- In May 2026, Apogee announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive capital.
Concerns
- Net loss increased primarily as a result of higher R&D and G&A expenses.
- Merger transaction costs were $ 4,361 (In thousands) for the three and six months ended June 30, 2026.
- The AbbVie acquisition remains subject to customary closing conditions, including shareholder approval and required regulatory approvals.
- The filing states that positive Phase 2 and Phase 1b interim results may not be predictive of results in later-stage or larger clinical trials.
What to watch
- Expected launch of planned zumilokibart Phase 3 trials this year.
- Initiation of the ELEVATE Phase 2a EoE trial in 2H 2026.
- APG279 Phase 1b interim data expected in 2H 2026.
- Additional APG273 plans expected in 2H 2026.
- Initiation of the ASPIRE Phase 2b asthma trial in 1H 2027.
- Closing of the proposed AbbVie acquisition expected in the third quarter of 2026.
Balance sheet and cash flow
- Cash and cash equivalents were $ 105,571 (In thousands) as of June 30, 2026, compared to $ 131,549 (In thousands) as of December 31, 2025.
- Marketable securities were $ 866,355 (In thousands) as of June 30, 2026, compared to $ 598,643 (In thousands) as of December 31, 2025.
- Long-term marketable securities were $ 321,943 (In thousands) as of June 30, 2026, compared to $ 172,730 (In thousands) as of December 31, 2025.
- Total current assets were $ 991,733 (In thousands) as of June 30, 2026, compared to $ 741,358 (In thousands) as of December 31, 2025.
- Total assets were $ 1,335,813 (In thousands) as of June 30, 2026, compared to $ 937,134 (In thousands) as of December 31, 2025.
- Accounts payable were $ 3,080 (In thousands) as of June 30, 2026, compared to $ 1,221 (In thousands) as of December 31, 2025.
- Accrued expenses and other current liabilities were $ 32,065 (In thousands) as of June 30, 2026, compared to $ 23,181 (In thousands) as of December 31, 2025.
- Revenue share liability was $ 99,231 (In thousands) as of June 30, 2026, compared to — as of December 31, 2025.
- Total liabilities were $ 141,209 (In thousands) as of June 30, 2026, compared to $ 33,251 (In thousands) as of December 31, 2025.
- Total stockholders' equity was $ 1,194,604 (In thousands) as of June 30, 2026, compared to $ 903,883 (In thousands) as of December 31, 2025.
- No operating cash flow, free cash flow, or debt balance was reported in the filing text.
Analysis
Apogee reported a net loss of $85.9 million for the quarter ended June 30, 2026, compared with a net loss of $66.1 million for the quarter ended June 30, 2025. Research and development expenses were $67.3 million versus $55.7 million, while general and administrative expenses were $24.3 million versus $17.5 million. The quarter also included $ 4,361 (In thousands) of merger transaction costs. The filing attributes the increased R&D spend to continued development of zumilokibart and higher personnel and equity-based compensation costs, while G&A rose with headcount, personnel-related expenses and the fair value of equity awards.
The clinical update was the principal operating development. In APEX Phase 2 Part B, 65.9% of patients receiving mid-dose zumilokibart achieved EASI-75, with 41.9% placebo adjusted. Reported secondary outcomes included IGA 0/1 in 46.0% of patients, EASI-90 in 47.4%, I-NRS ≥4 improvement in 50.5%, EASI-100 in 16.5%, and very low disease activity in 20.6%. The company selected the mid-dose regimen for planned Phase 3 initiation this year.
Liquidity expanded materially from the prior-year position cited in the release. Cash, cash equivalents, marketable securities and long-term marketable securities were $1.3 billion as of June 30, 2026, compared with $621.2 million as of June 30, 2025. The balance sheet also reported a $ 99,231 (In thousands) revenue share liability as of June 30, 2026. Management previously announced a Blackstone Life Sciences financing collaboration for up to $1.3 billion in flexible, non-dilutive capital to support Phase 3 development and potential commercialization of zumilokibart.
The corporate outcome now centers on the pending AbbVie transaction. AbbVie agreed to acquire all outstanding Apogee shares for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions. Pipeline execution remains active during the pendency of the transaction, with ELEVATE in EoE planned for 2H 2026, APG279 interim data expected in 2H 2026, additional APG273 plans expected in 2H 2026, and ASPIRE in asthma planned for 1H 2027.
Management, verbatim
The second quarter marked a transformational period for Apogee.
Michael Henderson, M.D., Chief Executive Officer of Apogee Therapeutics
Not in the filing
stated, not guessed- Total revenue was not reported.
- Segment revenue and segment comparisons were not reported.
- Gross profit and gross margin were not reported.
- GAAP and non-GAAP earnings per share were not reported.
- Non-GAAP financial metrics were not reported.
- Operating cash flow and free cash flow were not reported.
- Debt balance was not reported.
- Share repurchases and dividends were not reported.
- Formal financial guidance for revenue, gross margin, operating expenses, or tax rate was not reported.
- Prior-quarter comparisons and reported year-over-year or quarter-over-quarter percentage changes were not provided for the reported financial line items.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Apogee is a clinical-stage immunology/biologics company with zumilokibart in atopic dermatitis and plans to expand into EoE and asthma.
Ticker impact
Apogee disclosed a pending AbbVie acquisition at $135.11 per share plus Q2 results and Phase 2 APEX Part B endpoint data.
Near-term upside bias versus deal floor is possible on deal-confidence and regulatory/approval expectations, while volatility can rise around closing conditions and any trial-related updates.
The filing adds primary, time-sensitive deal terms (price, equity value, expected Q3 close) and fresh efficacy/tolerability endpoint details that can influence shareholder sentiment and deal certainty.
Market effects
Biotech M&A and immunology deal appetite may get a sentiment boost, but the impact is mostly company-specific given the single-name focus.
Limited, primarily affecting US Nasdaq biotech sentiment rather than broad regional flows.
AbbVie’s global commercialization intent could reinforce cross-border immunology M&A narratives, but no additional global regulatory facts were disclosed.
Counterpoint
Deal spreads can widen if regulatory review or shareholder approval risk increases, even with a stated $135.11 offer price.
Key entities
- issuerApogee Therapeutics, Inc.
Nasdaq-listed clinical-stage biotech; disclosed Q2 2026 results, APEX Part B data, and a definitive AbbVie acquisition agreement.
- acquirerAbbVie
Agreed to acquire all outstanding Apogee shares for $135.11 per share in cash; expected to close in Q3 2026 subject to conditions.
- financing_partnerBlackstone Life Sciences
Entered a strategic financing collaboration with Apogee for up to $1.3 billion of flexible, non-dilutive capital.
- pipeline_assetzumilokibart
Apogee’s lead program; Part B induction dose optimization results support mid-dose selection for planned Phase 3 and advancement this year.
